{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:50:46Z","timestamp":1791496246148,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jhep.2012.11.039","type":"journal-article","created":{"date-parts":[[2012,12,3]],"date-time":"2012-12-03T23:12:10Z","timestamp":1354576330000},"page":"676-683","source":"Crossref","is-referenced-by-count":238,"title":["Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: Finite treatment duration unlikely"],"prefix":"10.1016","volume":"58","author":[{"given":"St\u00e9phane","family":"Chevaliez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Grare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.11.039_b0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","article-title":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B","volume":"32","author":"Chan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2012.11.039_b0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","article-title":"Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia","volume":"52","author":"Nguyen","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.039_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.jhep.2012.11.039_b0020","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0040","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0045","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/hep.24473","article-title":"The clinical utility of HBsAg quantitation in chronic hepatitis B patients: a review","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0050","doi-asserted-by":"crossref","unstructured":"Kim SS, Lee D, Lee MH, Cheong JY, Cho SW. Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatol Res, in press, http:\/\/dx.doi.org\/10.1111\/j.1872-034X.2012.01065.x.","DOI":"10.1111\/j.1872-034X.2012.01065.x"},{"key":"10.1016\/j.jhep.2012.11.039_b0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0060","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jmv.22089","article-title":"Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B","volume":"83","author":"Lee","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2012.11.039_b0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e328352224d","article-title":"Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients","volume":"26","author":"Maylin","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2012.11.039_b0070","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2893.2012.01599.x","article-title":"Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels","volume":"19","author":"Shin","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2012.11.039_b0075","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcv.2010.12.008","article-title":"Correlation between the Elecsys HBsAg II assay and the architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum","volume":"50","author":"Wursthorn","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2012.11.039_b0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcv.2011.04.005","article-title":"A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"51","author":"Sonneveld","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2012.11.039_b0085","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.11.039_b0095","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.11.039_b0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350701200107","article-title":"Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels","volume":"12","author":"Manesis","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2012.11.039_b0105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"Reijnders","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.039_b0110","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0115","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues","volume":"16","author":"Jaroszewicz","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2012.11.039_b0120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"Zoutendijk","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2012.11.039_b0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP1723","article-title":"Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients","volume":"16","author":"Thibault","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2012.11.039_b0130","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/JCM.01306-10","article-title":"Performance of version 2.0 of the Cobas AmpliPrep\/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification","volume":"48","author":"Chevaliez","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2012.11.039_b0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.22634","article-title":"Complex dynamics of hepatitis B virus resistance to adefovir","volume":"49","author":"Pallier","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.510290119","article-title":"Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance","volume":"29","author":"Pichoud","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1099\/0022-1317-81-1-67","article-title":"A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness","volume":"81","author":"Stuyver","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2012.11.039_b0150","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/S0168-8278(10)61007-0","article-title":"HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment","volume":"52","author":"Gane","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.039_b0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jhep.2009.12.020","article-title":"A new role for an old marker, HBsAg","volume":"52","author":"Brunetto","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.039_b0160","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","article-title":"A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B","volume":"52","author":"Chan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.039_b0165","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1440-1746.2010.06282.x","article-title":"Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients","volume":"25","author":"Ma","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2012.11.039_b0170","first-page":"151","article-title":"On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alpha-2a","volume":"4","author":"Marcellin","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2012.11.039_b0175","first-page":"152","article-title":"On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months pots-treatment in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alpha-2a","volume":"4","author":"Piratvisuth","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2012.11.039_b0180","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1111\/j.1365-2893.2011.01473.x","article-title":"Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients","volume":"18","author":"Gramenzi","year":"2011","journal-title":"J Viral Hepat"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812009099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812009099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T10:59:28Z","timestamp":1687863568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812009099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0168827812009099"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.11.039","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}